These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31625972)

  • 1. Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations.
    Ando K; Inoue T; Hikishima K; Komaki Y; Kawai K; Inoue R; Nishime C; Nishinaka E; Urano K; Okano H
    Behav Pharmacol; 2020 Feb; 31(1):45-60. PubMed ID: 31625972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease.
    Ando K; Obayashi S; Nagai Y; Oh-Nishi A; Minamimoto T; Higuchi M; Inoue T; Itoh T; Suhara T
    PLoS One; 2012; 7(10):e46371. PubMed ID: 23056291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets.
    Ando K; Maeda J; Inaji M; Okauchi T; Obayashi S; Higuchi M; Suhara T; Tanioka Y
    Psychopharmacology (Berl); 2008 Jan; 195(4):509-16. PubMed ID: 17879087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
    Waters CM; Hunt SP; Jenner P; Marsden CD
    Neuroscience; 1987 Dec; 23(3):1025-39. PubMed ID: 2893993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
    Kupsch A; Sautter J; Schwarz J; Riederer P; Gerlach M; Oertel WH
    Brain Res; 1996 Nov; 741(1-2):185-96. PubMed ID: 9001722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease.
    Mavridis M; Degryse AD; Lategan AJ; Marien MR; Colpaert FC
    Neuroscience; 1991; 41(2-3):507-23. PubMed ID: 1870701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson Disease: Diffusion MR Imaging to Detect Nigrostriatal Pathway Loss in a Marmoset Model Treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Hikishima K; Ando K; Yano R; Kawai K; Komaki Y; Inoue T; Itoh T; Yamada M; Momoshima S; Okano HJ; Okano H
    Radiology; 2015 May; 275(2):430-7. PubMed ID: 25602507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective effects of bee venom pharmaceutical acupuncture in acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
    Doo AR; Kim ST; Kim SN; Moon W; Yin CS; Chae Y; Park HK; Lee H; Park HJ
    Neurol Res; 2010 Feb; 32 Suppl 1():88-91. PubMed ID: 20034453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
    Albanese A; Granata R; Gregori B; Piccardi MP; Colosimo C; Tonali P
    Neuroscience; 1993 Aug; 55(3):823-32. PubMed ID: 8105418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    Hayley S; Crocker SJ; Smith PD; Shree T; Jackson-Lewis V; Przedborski S; Mount M; Slack R; Anisman H; Park DS
    J Neurosci; 2004 Feb; 24(8):2045-53. PubMed ID: 14985447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Ando K; Inoue T; Itoh T
    Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
    Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y
    Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage.
    Franke SK; van Kesteren RE; Wubben JA; Hofman S; Paliukhovich I; van der Schors RC; van Nierop P; Smit AB; Philippens IH
    Neuroscience; 2016 Jan; 312():247-59. PubMed ID: 26431624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets.
    Perry TL; Jones K; Hansen S; Wall RA
    Neurosci Lett; 1987 Mar; 75(1):65-70. PubMed ID: 3106859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individual and Familial Susceptibility to MPTP in a Common Marmoset Model for Parkinson's Disease.
    Franke SK; van Kesteren RE; Hofman S; Wubben JA; Smit AB; Philippens IH
    Neurodegener Dis; 2016; 16(5-6):293-303. PubMed ID: 26999593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.
    Obinu MC; Reibaud M; Blanchard V; Moussaoui S; Imperato A
    Mov Disord; 2002 Jan; 17(1):13-9. PubMed ID: 11835434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurometabolic profiles of the substantia nigra and striatum of MPTP-intoxicated common marmosets: An in vivo proton MRS study at 9.4 T.
    Heo H; Ahn JB; Lee HH; Kwon E; Yun JW; Kim H; Kang BC
    NMR Biomed; 2017 Feb; 30(2):. PubMed ID: 28028868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olfactory impairment and Parkinson's disease-like symptoms observed in the common marmoset following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Miwa T; Watanabe A; Mitsumoto Y; Furukawa M; Fukushima N; Moriizumi T
    Acta Otolaryngol Suppl; 2004 Aug; (553):80-4. PubMed ID: 15277042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.